trending Market Intelligence /marketintelligence/en/news-insights/trending/CYM8mNdCaURNGPQR3XrgDA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Albireo Pharma seeks approval for chronic constipation drug in Japan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Albireo Pharma seeks approval for chronic constipation drug in Japan

Albireo Pharma Inc. said EA Pharma Co. Ltd. filed a new drug application to the Japanese Pharmaceuticals and Medical Devices Agency for elobixibat, a chronic constipation drug.

EA Pharma holds the exclusive license for elobixibat as gastrointestinal disorder treatment in Japan and other select countries in Asia.

If approved, EA Pharma will co-market the drug in Japan with Mochida Pharmaceutical Co. Ltd.

Elobixibat is an orally available ileal bile acid transporter inhibitor that helps improve secretion and motility in the large bowel. In a phase 3 clinical trial, the drug met the primary endpoint, change in the number of weekly spontaneous bowel movements from baseline to the first treatment week compared with placebo, with high statistical significance.